The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma

Human Pathology

Volumn 27, Issue 6, 1996, Pages 567-572

  Papadaki, Helen ^a   Finkelstein, Sydney D ^a   Kounelis, Sophia ^a   Bakker, Anke ^a   Swalsky, Patricia A ^a   Kapadia, Silloo B ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

adenoid cystic carcinoma; genotype; immunohistochemistry; p53; point mutation; tumor suppresser genes; WAF 1

Indexed keywords

DNA; OLIGONUCLEOTIDE; PROTEIN P53;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; DNA SEQUENCE; FEMALE; GENE MUTATION; GENOTYPE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0029970176     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90163-X     Document Type: Article

References (32)

1. Tomich CE: Adenoid cystic carcinoma, in Ellis GE, Auclair PL, Gnepp DR (ed): Surgical Pathology of the Salivary Glands. Philadelphia, Saunders, 1991, pp 333-349
2. Spiro RH, Huvos AG, Strong EW: Adenoid cystic carcinoma of salivary origin: A clinicopathologic study of 242 cases. Am J Surg 128:512-520, 1974
3. Peel RL, Gnepp DR Diseases of the salivary glands, in Barnes L (ed): Surgical Pathology of the Head and Neck. New York, NY, Dekker, 1985, pp 533-645
4. Matsuba HM, Spector GJ, Thawley SE, et al: Adenoid cystic salivary gland carcinoma: A histopathologic review of treatment failure patterns. Cancer 67:519-524, 1986
5. Nascimento AG, Amaral ALP, Prado LAF, et al: Adenoid cystic carcinomas of salivary glands: A study of 61 cases with clinicopathologic correlation. Cancer 57:312-319, 1986
6. Perzon KH, Gullang P, Clairmont AC: Adenoid cystic carcinoma arising in salivary glands: A correlation of histologic features and clinical course. Cancer 42:265-282, 1978
7. Batsakis JG, Luna MA, El-Naggar A: Histopathologic grading of salivary gland neoplasms. III. Adenoid cystic carcinomas. Ann Otol Rhinol Laryngol 99:1007-1009, 1990
8. Spiro RH, Huvos AG: Stage means more than grade in adenoid cystic carcinoma. Am J Surg 164:623-628, 1992
9. Spiro RH, Huvos AG, Strong EW: Adenoid cystic carcinoma: Factors influencing survival. Am J Clin Pathol 138:579-583, 1979
10. Szanto PA, Luna MA, Tortoledo ME, et al: Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 54:1062-1069, 1984
11. Levine AJ, MomandJ, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991
12. Potter V, Pzvokocimer M: P53 and human malignancies. Adv Cancer Res 57:257-272, 1991
13. Hall PA, Lane DP: p53 In tumor pathology: Can we trust immunohistochemistry? Revisited. J Pathol 172:1-4, 1994
14. Hollstein M, Sidransky D, Vogelstein B, et al: p53 Mutations in human cancers. Science 253:49-53, 1991
15. Soussi T, Legros Y, Lubin R, et al: Multifactorial analysis of p53 alterations in human cancer: A review. Int J Cancer 57:1-9, 1994
16. Lane DP, Benchimol S: P53 oncogene or anti-oncogenes. Genes Dev 4:108, 1990
17. Donehower L, Bradley A: The tumor suppressor p53. Biochem Biophys Acta 1155:181-205, 1993
18. Harris CC, Hollstein M: Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329:1318-1327, 1993
19. Soini Y, Kamel D, Nuorva K, et al: Low p53 protein expression in salivary gland tumors compared with lung carcinomas. Virchows Arch [A] 421:415-420, 1992
20. Jiang Y, He AG, Dai XC: The immunohistolochemical study of p53 protein in primary lung cancer. Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih 17:45-46, 1994
21. Prives C, Manfredi JJ: The p53 tumor suppressor protein: Meeting review. Genes Dev 7:529-534, 1993
22. Bruner JM, Connelly JH, Saya H: p53 Protein immunostaining in routinely processed paraffin embedded sections. Mod Pathol 6:189-194, 1993
23. Vojttesen B, BartekJ, Migley CA, et al: An immunochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 151:237-244, 1992
24. Iggo R, Gatter K, Bartek J, et al: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679, 1990
25. GannoyJV, Greaves R, Iggo R, et al: Activating mutations in p53 produce a common conformational effect: A monoclonal antibody specific for the mutant form. EMBOJ 39:1595-1602, 1990
26. Papadaki H, Kounelis S, Kapadia SB, et al: Role of p53 in development and recurrence of olfactory neuroblastoma. Am J Surg Pathol 20: 1996 (in press)
27. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF-I a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
28. Harper JW, Adami GR, Wei N, et al: The p21 cdk-interacting protein Cipl is a potential inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
29. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
30. Finkelstein SD, Sayegh R, Christensen S, et al: Genotypic classification of colorectal adenocarcinoma. Cancer 71:3827-3838, 1993
31. Finkelstein SD, Sayegh R, Bakker A, et al: Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 128:526-532, 1993
32. Finkelstein SD, Przygodski R, Pricolo VE, et al: K-ras-2 topographic genotyping of pancreatic adenocarcinoma. Arch Surg 129:367-373, 1994